Humabs

What Humabs does

Humabs BioMed SA is a Swiss biotechnology company headquartered in Bellinzona, Switzerland that discovers and develops anti-infective immunotherapies using its proprietary CellClone technology platform. The platform screens and selects highly effective naturally occurring human monoclonal antibodies from memory B cells and plasma cells derived from convalescent patients, enabling rapid identification and engineering of ultra-potent antibodies for prophylactic, therapeutic, or diagnostic purposes against viral and bacterial infections. Its pipeline of more than fifteen development candidates spans targets including Ebola, Zika, Rabies, Dengue, chronic hepatitis B, and RSV/MPV infections, with a Public Health portfolio addressing major outbreak threats developed in cooperation with government and not-for-profit health organizations.

Humabs operates as a wholly-owned subsidiary of Vir Biotechnology, acquired in October 2017, and functions primarily as Vir's antibody discovery engine with operations extending through early-stage clinical development up to clinical proof of concept. The scientific foundation originates from the laboratory of Prof. Antonio Lanzavecchia, Director of the Institute for Research in Biomedicine (IRB) in Switzerland and Humabs' scientific founder. Notable technical milestones include a Phase 1 Ebola antibody trial completed at the NIH Clinical Center in January 2019 and peer-reviewed publications in Cell (Zika bi-specific antibody, September 2017) and PNAS (Zika diagnostic assay with UC Berkeley, July 2017).

The business model is R&D-focused rather than commercialized sales: Humabs develops antibody candidates through early-stage clinical development and out-licenses or partners them with larger pharmaceutical companies for late-stage development and commercialization. Revenue is generated through licensing and royalty arrangements rather than direct product sales, with parent-company Vir Biotechnology serving as the primary internal customer for discovered assets. The company maintains a small footprint (11-50 employees) and its go-to-market relies on scientific publications, partnership announcements, and institutional collaborations rather than traditional sales channels.

Name

Humabs

Legal name

Humabs BioMed SA

Website

https://humabs.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Humabs BioMed is a Swiss antibody-discovery biotech that uses its proprietary CellClone platform to isolate human monoclonal antibodies from convalescent patients for treating viral and bacterial infections; it operates as a wholly-owned subsidiary of Vir Biotechnology.

Ownership category

akta.pro rank

Headquarters

HQ city

Bellinzona

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Anti-infective Immunotherapy Development: Humabs focuses on discovering and developing anti-infective immunotherapies up to clinical proof of concept. The company has a broad pipeline of more than fifteen development candidates for viral and bacterial diseases. Revenue generation would occur through out-licensing, partnerships, or eventual product commercialization upon successful clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Humabs BioMed SA is a Swiss biopharmaceutical company that develops anti-infective immunotherapies based on human monoclonal antibodies. The company isolates antibodies from convalescent patients using its proprietary CellClone technology platform and advances therapeutic candidates through preclinical and clinical proof-of-concept stages for diseases such as Ebola, Zika, Rabies, Dengue, chronic hepatitis B, and RSV/MPV infections.

Product overview

Humabs BioMed is a biotechnology company that develops anti-infective immunotherapies using its proprietary CellClone Technologies platform. The company focuses on discovering and developing antibody-based treatments up to clinical proof of concept. Their pipeline includes programs targeting Ebola, Zika, Rabies, Dengue, chronic hepatitis B, and RSV/MPV infections. Humabs operates as a subsidiary of Vir Biotechnology.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Phase 1 clinical trial successfully concluded by NIH for Ebola antibody treatment (January 2019)
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered major, core and minor.

• Alnylam PharmaceuticalsmajorStrategic or Co-development Partner · 27 November 2018Vir Biotechnology and Alnylam Pharmaceuticals initiated a Phase 1/2 study of VIR-2218, a novel investigational RNAi therapeutic for treatment of chronic hepatitis B virus (HBV) infection.
• Vir BiotechnologycoreStrategic or Co-development Partner · 18 October 2017Humabs BioMed became a subsidiary of Vir Biotechnology in October 2017. Vir Biotechnology is a San Francisco-based company integrating diverse innovations in science, technology, and medicine to transform care of people with serious infectious diseases.
• NIH Clinical CentercoreStrategic or Co-development PartnerPhase 1 clinical trial to test safety of an Ebola antibody treatment was successfully concluded by the NIH Clinical Center in Bethesda, Maryland in January 2019.
• Institute for Research in Biomedicine (IRB)coreStrategic or Co-development PartnerCellClone technology originates from the laboratory of Prof. Antonio Lanzavecchia, Director of IRB in Switzerland and scientific founder of Humabs.
• University of California, BerkeleyminorStrategic or Co-development PartnerHumabs BioMed and UC Berkeley announced publication of data for a novel antibody-based assay to detect Zika virus infection in the peer-reviewed journal PNAS in July 2017.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/humabs-biomed

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Humabs